Relationships between structure and interaction kinetics for HIV-1 protease inhibitors

Journal of Medicinal Chemistry

Volumn 45, Issue 25, 2002, Pages 5430-5439

  Markgren, Per Olof ^a   Schaal, Wesley ^a   Hämäläinen, Markku ^a   Karlén, Anders ^a   Hallberg, Anders ^a   Samuelsson, Bertil ^b,c   Danielson, U Helena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BIACORE AB   (Sweden)

^c MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 (NAPHTHOXYACETYL)HISTIDYL(5 AMINO 6 CYCLOHEXYL 3,4 DIHYDROXY 2 ISOPROPYLHEXANOYL)ISOLEUCINE N (2 PYRIDYLMETHYL)AMIDE; AMPRENAVIR; LEAD; PROTEINASE INHIBITOR; SULFAMIDE DERIVATIVE; UREA;

ARTICLE; BINDING AFFINITY; BIOSENSOR; CYCLIZATION; DISSOCIATION; HUMAN IMMUNODEFICIENCY VIRUS 1; KINETICS; MOLECULAR INTERACTION; SURFACE PLASMON RESONANCE;

BIOSENSING TECHNIQUES; HIV PROTEASE; HIV PROTEASE INHIBITORS; KINETICS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; UREA;

EID: 0037028049     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0208370     Document Type: Article

References (46)

1. Jönsson, U.; Fägerstam, L.; Ivarsson, B.; Johnsson, B.; Karlsson, R.; Lundh, K.; Löfås, S.; Persson, B.; Roos, H.; Rönnberg, I.; et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 1991, 11, 620-627.
2. Rich, R. L.; Myszka, D. G. Advances in surface plasmon resonance biosensor analysis. Curr. Opin. Biotechnol. 2000, 11, 54-61.
3. Markgren, P.-O.; Lindgren, M. T.; Gertow, K.; Karlsson, R.; Hämäläinen, M.; Danielson, U. H. Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. Anal. Biochem. 2001, 291, 207-218.
4. Tomasselli, A. G.; Heinrikson, R. L. Targeting the HIV-protease in AIDS therapy: A current clinical perspective. Biochim. Biophys. Acta 2000, 1477, 189-214.
5. Richman, D. D. HIV chemotherapy. Nature 2001, 410, 995-1001.
6. Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 protease: A major success of structure assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 249-284.
7. Thaisrivongs, S.; Strohbach, J. W. Structure-based discovery of Tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 1999, 51, 51-58.
8. Maschera, B. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 1996, 271, 33231-33235.
9. Porter, D. J.; Hanlon, M. H.; Carter, L. H., Ill; Danger, D. P.; Furfine, E. S. Effectors of HIV-1 protease peptidolytic activity. Biochemistry 2001, 40, 11131-11139.
10. Xie, D.; Gulnik, S.; Erickson, J. W. Dissection of binding energy with native and ligand-bound protein stabilities: Determining the affinity of ultratight-binding inhibitors of HIV-1 protease and its drug resistant mutants. J. Am. Chem. Soc. 2000, 122, 11533-11534.
11. Markgren, P.-O.; Hämäläinen, M.; Danielson, U. H. Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology. Anal. Biochem. 2000, 279, 71-78.
12. Hämäläinen, M. D.; Markgren, P.-O.; Schaal, W.; Karlén, A.; Classon, B.; Vrang, L.; Samuelsson, B.; Hallberg, A.; Danielson, U. H. Characterization of a set of HIV-1 protease inhibitors using binding kinetic data from a biosensor-based screen. J. Biomol. Screening 2000, 5, 353-359.
13. Markgren, P.-O.; Lindgren, M. T.; Gertow, K.; Karlsson, R.; Hämäläinen, M. D.; Danielson, U. H. Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. Anal. Biochem. in press.
14. Nillroth, U.; Vrang, L.; Markgren, P.-O.; Hultén, J.; Hallberg, A.; Danielson, U. H. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs. Antimicrob. Agents Chemother. 1997, 41, 2383-2388.
15. Karlsson, R. Affinity analysis of non-steady-state data obtained under mass transport limited conditions using BIAcore technology. J. Mol. Recognit. 1999, 12, 285-292.
16. Fersht, A. Structure and Mechanism in Protein Science. A Guide to Enzyme Catalysis and Protein Folding; W. H. Freeman and Company: New York, 1999.
17. 18O isotope exchange. Biochemistry 1991, 30, 8441-8453.
18. Wondrak, E. M.; Louis, J. M.; Oroszlan, S. The effect of salt on the Michaelis Menten constant of the HIV-1 protease correlates with the Hofmeister series. FEBS Lett. 1991, 280, 344-346.
19. Szeltner, Z.; Polgar, L. Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration. J. Biol. Chem. 1996, 271, 5458-5463.
20. Bäckbro, K.; Löwgren, S.; Österlund, K.; Atepo, J.; Unge, T.; Hultén, J.; Bonham, N. M.; Schaal, W.; Karlén, A.; Hallberg A. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J. Med. Chem. 1997, 40, 898-902.
21. Schaal, W.; Karlsson, A.; Ahlsén, G.; Lindberg, J.; Andersson, H. O.; Danielson, U. H.; Classon, B.; Unge, T.; Samuelsson, B.; Hultén, J.; Hallberg, A.; Karlén, A. Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. J. Med. Chem. 2001, 44, 155-169.
22. Berezov, A.; Zhang, H.-T.; Greene, M. I.; Murali, R. Biacore analysis of rationally designed anti-HER2 exocyclic mimetics of antibodies. Biajournal 2001, 8, 4-7.
23. Markgren, P.-O.; Hämäläinen, M.; Danielson, U. H. Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology. Anal. Biochem. 1998, 265, 340-350.
24. 2 symmetric potential inhibitors of HIV-1 protease from D-mannitol. J. Carbohydr. Chem. 1996, 15, 555-569.
25. Nöteberg, D.; Brånalt, J.; Kvarnström, I.; Classon, B.; Samuelsson, B.; Nillroth, U.; Danielson, U. H.; Karlén, A.; Hallberg, A. Synthesis of enantiomerically pure cis and trans 2-aminocyclopentanecarboxylic acids. Use of proline replacements in potential HIV-protease inhibitors. Tetrahedron 1997, 53, 7975-7984.
26. Hultén, J.; Bonham, N. M.; Nillroth, U.; Hansson, T.; Zuccarello, G.; Bouzide, A.; Åqvist, J.; Classon, B.; Danielson, U. H.; Karlén, A.; Kvarnström, I.; Samuelsson, B.; Hallberg, A. Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies, and computational predictions of binding afinities. J. Med. Chem. 1997, 40, 885-897.
27. Brånalt, J.; Kvarnström, I.; Classon, B.; Samuelsson, B.; Nillroth, U.; Danielson, U. H.; Karlén, A.; Hallberg, A. A convenient synthesis of 1-(S)-[1′-(S)-(tert-butyloxycarbonylamino)-2′-phenethyl]oxirane. A useful building block in synthesis of HIV protease inhibitors. Tetrahedron Lett. 1997, 38, 3483-3486.
28. 2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. J. Med. Chem. 1998, 41, 3782-3792.
29. Zuccarello, G.; Bouzide, A.; Kvarnström, I.; Niklasson, G.; Svensson, S. C. T.; Brisnader, M.; Danielson, H.; Nillroth, U.; Karlén, A.; Hallberg, A.; Classon, B.; Samuelson, B. HIV-1 protease inhibitors based on acyclic carbohydrates. J. Org. Chem. 1998, 63, 4898-4906.
30. 2-symmetric P1/P1′-modified HIV-1 protease inhibitors. J. Med. Chem. 1999, 42, 3835-3844.
31. SYBYL, Version 6.5; Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144.
32. MOPAC 6.0: Quantum Chemistry Program Exchange #455, Indiana University, 1990.
33. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
34. Moriguchi, I.; Hirono, S.; Liu, Q.; Nakagome, I.; Matshushita, Y. Simple method of calculating octanol/water partition coefficient. Chem. Pharm. Bull. (Tokyo) 1992, 40, 1.
35. Moriguchi, I.; Hirono, S.; Nakagome, I.; Hirano, H. Comparison of reliability of logP values for drugs calculated by several methods. Chem. Pharm. Bull. (Tokyo) 1994, 42, 4.
36. Bodor, N.; Gabanyi, Z.; Wong, C. K. A new method for the estimation of partition-coefficient. J. Am. Chem. Soc. 1989, 111, 3783-3786.
37. Pearlman, R. S.; Skell, J. M.; Deanda F. S., III. Laboratory for Molecular Graphics and Theoretical Modeling; College of Pharmacy, University of Texas: Austin, TX.
38. SIMCA, Version 6.0; Umetrics AB, Box 7960, SE-907 19 Umeå, Sweden.
39. Kennard, R. W.; Stone, L. A. Computer aided design of experiments. Technometrics 1969, 11, 137-148.
40. Glaser, R. W. Antigen-antibody binding and mass transport by convection and diffusion to a surface: A two-dimensional computer model of binding and dissociation kinetics. Anal. Biochem. 1993, 213, 152-161.
41. 2-symmetric HIV-1 protease: Nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2′ side chains. J. Med. Chem. 1999, 42, 4054-4061.
42. Wachtmeister, J.; Mühlman, A.; Classon, B.; Kvarnström, I.; Hallberg, A.; Samuelsson, B. Impact of the central hydroxyl groups on the activity of symmetrical HIV-1 protease inhibitors derived from L-mannaric acid. Tetrahedron 2000, 56, 3219-3225.
43. Mühlman, A.; Lindberg, J.; Classon, B.; Unge, T.; Hallberg, A.; Samuelsson, B. Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal. J. Med. Chem. 2001, 44, 3407-3416.
44. 2 symmetric template. Can. J. Chem. 2000, 78, 829-837.
45. Nillroth, U.; Besidsky, Y.; Classon, B.; Chattopadhyaya, J.; Ugi, I.; Danielson U. H. Specific interaction between HIV-1 proteinase and 5′-phosphate peptidomimetic derivatives of nucleoside analogues. Drug Des. Discovery 1995, 13, 43-54.
46. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994, 263, 380-384.